poisar

Stocks · News reference

RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DXCM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia

    ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.

    DXCM
  2. Gianni di Poce

    The Insider Report: The Leaders Have Taken Off

    Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the

    DXCMPTRNZLAB